Natera Inc reports results for the quarter ended June 30 - Earnings Summary
08/08/2025 05:51
Natera Inc NTRA.OQ reported a quarterly adjusted loss of 74 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 62 cents per share. Wall Street expected results to range from -75 cents to -40 cents per share. Revenue rose 32.2% to $546.60 million from a year ago; analysts expected $476.29 million. Natera Inc's reported EPS for the quarter was a loss of 74 cents. The company reported a quarterly loss of $100.94 million. Natera Inc shares had fallen by 18.2% this quarter and lost 12.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 2.1% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy" Wall Street's median 12-month price target for Natera Inc is $197.50, about 28.6% above its last closing price of $141.08 This summary was machine generated from LSEG data August 8 at 04:50 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.62 | -0.74 | Missed |
| Mar. 31 2025 | -0.64 | -0.50 | Beat |
| Dec. 31 2024 | -0.39 | -0.41 | Missed |
| Sep. 30 2024 | -0.57 | -0.26 | Beat |
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers